{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:19:12Z","timestamp":1760141952550,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00417-025-06885-8","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:10:20Z","timestamp":1751519420000},"page":"2541-2550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term remission and incidence of recurrence of neovascularization in intravitreal injection treated exudative age-related macular degeneration"],"prefix":"10.1007","volume":"263","author":[{"given":"Jen-Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4657-9113","authenticated-orcid":false,"given":"Cheng-Kuo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chyi-Huey","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Yi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"6885_CR1","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/s2214-109x(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV et al (2017) Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health 5:e1221\u2013e1234. https:\/\/doi.org\/10.1016\/s2214-109x(17)30393-5","journal-title":"Lancet Glob Health"},{"key":"6885_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/IAE.0b013e3181babd8e","volume":"30","author":"EW Gower","year":"2010","unstructured":"Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM (2010) A cost-effectiveness analysis of three treatments for age-related macular degeneration. Retina 30:212\u2013221. https:\/\/doi.org\/10.1097\/IAE.0b013e3181babd8e","journal-title":"Retina"},{"key":"6885_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R (2015) Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 160:725-731e721. https:\/\/doi.org\/10.1016\/j.ajo.2015.06.023","journal-title":"Am J Ophthalmol"},{"key":"6885_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/iae.0000000000003690","volume":"43","author":"HS Fang","year":"2023","unstructured":"Fang HS, Bai CH, Cheng CK (2023) Strict pro re nata versus treat-and-extend regimens in neovascular age-related macular degeneration: a systematic review and meta-analysis. Retina 43:420\u2013432. https:\/\/doi.org\/10.1097\/iae.0000000000003690","journal-title":"Retina"},{"key":"6885_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4103\/tjo.TJO-D-22-00135","volume":"13","author":"J Charles","year":"2023","unstructured":"Charles J, Chau TTH (2023) Five-year outcome of Aflibercept intravitreal injection in Na\u00efve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen: results from a prospective observational study. Taiwan J Ophthalmol 13:219\u2013224. https:\/\/doi.org\/10.4103\/tjo.TJO-D-22-00135","journal-title":"Taiwan J Ophthalmol"},{"key":"6885_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ophtha.2015.10.034","volume":"123","author":"E Daniel","year":"2016","unstructured":"Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ et al (2016) Outcomes in eyes with retinal angiomatous proliferation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 123:609\u2013616. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.034","journal-title":"Ophthalmology"},{"key":"6885_CR7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/s0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258\u20131267. https:\/\/doi.org\/10.1016\/s0140-6736(13)61501-9","journal-title":"Lancet"},{"key":"6885_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajo.2017.06.002","volume":"180","author":"FC DeCroos","year":"2017","unstructured":"DeCroos FC, Reed D, Adam MK, Salz D, Gupta OP, Ho AC et al (2017) Treat-and-Extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol 180:142\u2013150. https:\/\/doi.org\/10.1016\/j.ajo.2017.06.002","journal-title":"Am J Ophthalmol"},{"key":"6885_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00417-017-3589-x","volume":"255","author":"N Feltgen","year":"2017","unstructured":"Feltgen N, Bertelmann T, Bretag M, Pfeiffer S, Hilgers R, Callizo J et al (2017) Efficacy and safety of a fixed bimonthly Ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial. Graefes Arch Clin Exp Ophthalmol 255:923\u2013934. https:\/\/doi.org\/10.1007\/s00417-017-3589-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6885_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","volume":"138","author":"PJ Kertes","year":"2020","unstructured":"Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M et al (2020) Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial. JAMA Ophthalmol 138:244\u2013250. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.5540","journal-title":"JAMA Ophthalmol"},{"key":"6885_CR11","doi-asserted-by":"publisher","first-page":"Cd012208","DOI":"10.1002\/14651858.CD012208.pub2","volume":"5","author":"E Li","year":"2020","unstructured":"Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G (2020) Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev 5:Cd012208. https:\/\/doi.org\/10.1002\/14651858.CD012208.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"6885_CR12","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/iae.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H (2021) Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the aries study: a randomized clinical trial. Retina 41:1911\u20131920. https:\/\/doi.org\/10.1097\/iae.0000000000003128","journal-title":"Retina"},{"key":"6885_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther 37:1173\u20131187. https:\/\/doi.org\/10.1007\/s12325-020-01236-x","journal-title":"Adv Ther"},{"key":"6885_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL et al (2024) Intravitreal Aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403:1141\u20131152. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1","journal-title":"Lancet"},{"key":"6885_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.oret.2017.07.009","volume":"2","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Grant S, Pirouz A (2018) Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat-extend-stop protocol. Ophthalmol Retina 2:225\u2013230. https:\/\/doi.org\/10.1016\/j.oret.2017.07.009","journal-title":"Ophthalmol Retina"},{"key":"6885_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/bjophthalmol-2020-316514","volume":"106","author":"D Jaggi","year":"2022","unstructured":"Jaggi D, Nagamany T, Ebneter A, Munk M, Wolf S, Zinkernagel M (2022) Aflibercept for age-related macular degeneration: 4-year outcomes of a \u2018treat-and-extend\u2019 regimen with exit-strategy. Br J Ophthalmol 106:246\u2013250. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316514","journal-title":"Br J Ophthalmol"},{"key":"6885_CR17","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","volume":"122","author":"Y Kuroda","year":"2015","unstructured":"Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A et al (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303\u20132310. https:\/\/doi.org\/10.1016\/j.ophtha.2015.06.053","journal-title":"Ophthalmology"},{"key":"6885_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/iae.0000000000001282","volume":"37","author":"WM Haddad","year":"2017","unstructured":"Haddad WM, Minous FL, Legeai J, Souied EH (2017) Long-term outcomes and incidence of recurrence of neovascularization in treated exudative age-related macular degeneration. Retina 37:951\u2013961. https:\/\/doi.org\/10.1097\/iae.0000000000001282","journal-title":"Retina"},{"key":"6885_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/bjophthalmol-2018-313447","volume":"104","author":"T Lin","year":"2020","unstructured":"Lin T, Dans KC, Muftuoglu IK, Meshi A, Amador-Patarroyo MJ, Cheng L et al (2020) Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. Br J Ophthalmol 104:58\u201363. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313447","journal-title":"Br J Ophthalmol"},{"key":"6885_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","volume":"6","author":"S Aslanis","year":"2022","unstructured":"Aslanis S, Amr\u00e9n U, Lindberg C, Epstein D (2022) Recurrent neovascular age-related macular degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen. Ophthalmol Retina 6:15\u201320. https:\/\/doi.org\/10.1016\/j.oret.2021.03.010","journal-title":"Ophthalmol Retina"},{"key":"6885_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12886-021-02231-8","volume":"22","author":"CK Cheng","year":"2022","unstructured":"Cheng CK, Chen SJ, Chen JT, Chen LJ, Chen SN, Chen WL et al (2022) Optimal approaches and criteria to treat-and-extend regimen implementation for neovascular age-related macular degeneration: experts consensus in Taiwan. BMC Ophthalmol 22:25. https:\/\/doi.org\/10.1186\/s12886-021-02231-8","journal-title":"BMC Ophthalmol"},{"key":"6885_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/iae.0000000000001572","volume":"38","author":"IK Muftuoglu","year":"2018","unstructured":"Muftuoglu IK, Alam M, You QS, Gaber R, Ramkumar HL, Mendoza N et al (2018) Long-term remission of neovascular age-related macular degeneration with as-needed anti-vascular endothelial growth factor therapy. Retina 38:516\u2013522. https:\/\/doi.org\/10.1097\/iae.0000000000001572","journal-title":"Retina"},{"key":"6885_CR23","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"RH Guymer","year":"2023","unstructured":"Guymer RH, Campbell TG (2023) Age-related macular degeneration. Lancet 401:1459\u20131472. https:\/\/doi.org\/10.1016\/S0140-6736(22)02609-5","journal-title":"Lancet"},{"key":"6885_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4263017","volume":"2017","author":"AC Pedrosa","year":"2017","unstructured":"Pedrosa AC, Sousa T, Pinheiro-Costa J, Beato J, Falc\u00e3o MS, Falc\u00e3o-Reis F et al (2017) Treatment of neovascular age-related macular degeneration with anti-VEGF agents: predictive factors of long-term visual outcomes. J Ophthalmol 2017:1\u201310. https:\/\/doi.org\/10.1155\/2017\/4263017","journal-title":"J Ophthalmol"},{"key":"6885_CR25","doi-asserted-by":"publisher","first-page":"15662","DOI":"10.1038\/s41598-022-07108-4","volume":"12","author":"HJ Cho","year":"2022","unstructured":"Cho HJ, Jeon YJ, Yoon W, Yoon J, Kim J, Kim JW (2022) Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission. Sci Rep 12:15662. https:\/\/doi.org\/10.1038\/s41598-022-07108-4","journal-title":"Sci Rep"},{"key":"6885_CR26","doi-asserted-by":"publisher","first-page":"e101057","DOI":"10.1371\/journal.pone.0101057","volume":"9","author":"CMG Cheung","year":"2014","unstructured":"Cheung CMG, Li X, Mathur R, Lee SY, Chan CM, Yeo I et al (2014) A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy. PLoS ONE 9:e101057. https:\/\/doi.org\/10.1371\/journal.pone.0101057","journal-title":"PLoS ONE"},{"key":"6885_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ajo.2015.12.024","volume":"164","author":"DSW Ting","year":"2016","unstructured":"Ting DSW, Ng WY, Ng SR, Tan SP, Yeo IYS, Mathur R et al (2016) Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Am J Ophthalmol 164:128-136e121. https:\/\/doi.org\/10.1016\/j.ajo.2015.12.024","journal-title":"Am J Ophthalmol"},{"key":"6885_CR28","doi-asserted-by":"publisher","first-page":"21572","DOI":"10.1038\/s41598-021-00904-4","volume":"11","author":"JY Kim","year":"2021","unstructured":"Kim JY, Son WY, Kim RY, Kim M, Park YG, Park Y-H (2021) Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results. Sci Rep 11:21572. https:\/\/doi.org\/10.1038\/s41598-021-00904-4","journal-title":"Sci Rep"},{"issue":"12","key":"6885_CR29","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaophthalmol.2017.4360","volume":"135","author":"YT Chi","year":"2017","unstructured":"Chi YT, Yang CH, Cheng CK (2017) Optical coherence tomography angiography for assessment of the 3-dimensional structures of polypoidal choroidal vasculopathy. JAMA Ophthalmol 135(12):1310\u20131316. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4360","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"6885_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tjo.2012.10.002","volume":"2","author":"PJ Chen","year":"2012","unstructured":"Chen PJ, Chen SN (2012) Clinical characteristics of exudative age-related. Macular degeneration in Taiwan. Taiwan J Ophthalmol 2(4):127\u2013130. https:\/\/doi.org\/10.1016\/j.tjo.2012.10.002","journal-title":"Taiwan J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06885-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06885-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06885-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:52:06Z","timestamp":1760075526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06885-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6885"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06885-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the Institutional Review Board (IRB) of Shin Kong Wu Ho-Su Memorial Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the IRB of Shin Kong Wu Ho-Su Memorial Hospital. This article does not include any animal studies conducted by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The IRB of Shin Kong Wu Ho-Su Memorial Hospital waived the requirement for informed consent due to the retrospective nature of the research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dr. Cheng-Kuo Cheng has participated in collaborative studies sponsored by Bayer, Roche, Novartis, and AbbVie, and has served as a consultant for these companies. All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}